Lexology July 9, 2021
Akin Gump Strauss Hauer & Feld LLP

Background on Cures 2.0

The COVID-19 pandemic response demonstrated the tremendous impact innovation can have on a global scale. The unprecedented experiences of the past year and a half have spurred renewed interest in accelerating the development of promising drugs and devices so that patients can benefit from medical advances as soon as possible. This is not the first time the Congress has considered how to more quickly and efficiently bring forward promising safe and effective treatments and cures to patients and ensure broader access to these technologies.

On December 13, 2016, President Obama signed the 21stCentury Cures Act into law. The Cures Act (P.L. 114-255) passed Congress with overwhelming bipartisan support and represented the culmination of a dedicated, multi-year...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Congress / White House, Cures Act, Govt Agencies, Patient / Consumer, Pharma / Biotech, Provider
What Washington wants in Cures 2.0
How ONC Can Strengthen Its HTI-1 Rule To Ensure Transparency, Fairness, And Equity In AI
Providers Take Note: The Common Agreement Version 2.0 Released
Advancing Nationwide, Trusted Health Information Networks
Cures Act tied to quicker release, access of imaging reports

Share This Article